Seattle Genetics Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Seattle Genetics Reports Third Quarter 2019 Financial Results
October 30, 2019 7:51 AM EDT
Needham & Company analyst Chad Messer reiterated a Buy rating and $121.00 price target on Seattle Genetics (NASDAQ: SGEN) following the company's 3Q earnings report. Seattle had several positive data readouts in 3Q including results from enfortumab vedotin (EV) at ESMO and topline pivotal tucatinib... More
October 30, 2019 7:44 AM EDT
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $140.00 price target on Seattle Genetics (NASDAQ: SGEN). With ongoing clinical momentum and against the backdrop of strong Adcetris sales, Fein believes Seattle Genetics is building a powerful value-driving structure upon its various assets.... More
October 29, 2019 4:14 PM EDT
Seattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.55), $0.19 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $213.26 million versus the consensus estimate of $211.83 million.
We are executing on our vision of becoming a multi-product global oncology company, recently achieving several important milestones across our late-stage pipeline, said Clay Siegall, Ph.D., President and Chief... More
